 Aptinyx Inc NASDAQ: APTX has restarted patient screening in a Phase 2 study evaluating NYX-458 in patients with mild cognitive impairment and mild dementia associated with Parkinsons disease and dementia with Lewy bodies. Aptinyx will release the data from this study in the second half of 2022. 